FDA Approves Votrient (pazopanib) for Advanced Form of Kidney Cancer
The U.S. Food and Drug Administration today approved Votrient (pazopanib), the sixth drug to be approved for kidney cancer since 2005.Votrient is an oral medication that interferes with angiogenesis, the growth of new blood vessels needed for solid tumors to grow and survive.Votrient is intended for people with advanced renal cell carcinoma, a type of kidney cancer in which the cancerous cells are found in the lining of very small tubes (tubules) in the kidney.
Aspirin and an Anti-Clotting Drug Reduces Dialysis Access Failure Risks
| May 22nd of 2009 |
Research
Renal |
For the first time, a combination of aspirin and the anti-platelet drug dipyridamole has been shown to significantly reduce blockages and extend the useful life of new artery-vein access grafts used for hemodialysis, according to a study by the Dialysis Access Consortium (DAC). The study, supported by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of the National Institutes of Health, will be published in the May 21, 2009, New England Journal of Medicine.
FDA Approves Drug for an Advanced Form of Kidney Cancer
| Mar 30th of 2009 |
Drugs
Renal |
The U.S. Food and Drug Administration today approved Afinitor oral tablets (everolimus) for the treatment of patients with advanced kidney cancer whose disease has progressed after treatment with other cancer therapies.
Chronic Kidney Disease Rises While Most Unaware of condition
| Nov 7th of 2007 |
Research
Renal |
A growing number of Americans have chronic kidney disease, but most remain unaware of it, hampering efforts to prevent irreversible kidney failure requiring dialysis or a transplant, according to a study funded by the National Institutes of Health and published November 7 in the Journal of the American Medical Association.
1
The Importance of Monitoring Vitamin D Status in the U.S.
Dr. Howard Nash
The NIH Common Fund's Human Microbiome Project
Read more